MedTrace Logo

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

NCT00004494 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-05-04

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome.

II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.

Conditions

  • Sepsis
  • Respiratory Distress Syndrome
  • Respiratory Distress Syndrome, Adult

Interventions

DRUG

vasoactive intestinal peptide

Sponsors & Collaborators

  • State University of New York

    collaborator OTHER

  • FDA Office of Orphan Products Development

    collaborator FED

  • Stony Brook University

    lead OTHER

Principal Investigators

  • Sami I. Said · State University of New York

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004494 on ClinicalTrials.gov